Floatz logo

Autologous Effector Lymphocytes Expanded Ex-Vivo

Myeloma

Dartmouth-Hitchcock Medical CenterCell therapyPhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

498 Active assets in the Myeloma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

Autologous Effector Lymphocytes Expanded Ex-Vivo is also rated in:

Transplant-eligible PatientsDormant
CCC
Indicative ·
52 / 100
View asset →
Autologous Effector LymphocytesDormant
CCC
Indicative ·
50 / 100
View asset →
follicular lymphomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →